siste dataoppdatering: 2011/10/17, 11:39
Website lasting tid
under test: 1.01 s
kabeltilkobling (gjennomsnitt): 1.06 s
DSL forbindelse (gjennomsnitt): 1.11 s
modem (gjennomsnitt): 3.68 s
HTTP-hoder
HTTP/1.1 200 OK
Cache-Control: private
Content-Length: 19171
Content-Type: text/html
Server: Microsoft-IIS/7.0
Set-Cookie: ASPSESSIONIDAADACCDD=BNCBKLCCGMJAPFGBNLAMCGFA; path=/
X-Powered-By: ASP.NET
Date: Mon, 17 Oct 2011 18:39:15 GMT
Connection: close
Informasjon om DNS-servere
algeta.no | MX | 10 | cluster4.eu.messagelabs.com | IN | 3600 |
algeta.no | MX | 20 | cluster4a.eu.messagelabs.com | IN | 3600 |
algeta.no | A | 85.221.23.130 | IN | 3600 | |
algeta.no | SOA | odin.intra.itera.no | helge.itera.no | 27 | 900 600 86400 3600 IN 3600 |
algeta.no | NS | odin.intra.itera.no | IN | 3600 | |
algeta.no | NS | labbetuss.net-works.no | IN | 3600 |
Mottatt fra den første DNS-server
Forespørsel til serveren "algeta.no"
Du brukte følgende DNS-server:
DNS Name: odin.intra.itera.no
DNS server adresse: 193.19.64.66#53
DNS server aliaser:
HEADER opcode: forespørsel, status: NOERROR, id: 36861
flagg: qr aa rd ra forespørsel: 1, Svar: 6, AUTHORITY: 0, ekstra: 4
forespørsel DEL:
algeta.no. IN ANY
Svar DEL:
algeta.no. 3600 IN A 85.221.23.130
algeta.no. 3600 IN NS labbetuss.net-works.no.
algeta.no. 3600 IN NS odin.intra.itera.no.
algeta.no. 3600 IN SOA odin.intra.itera.no. helge.itera.no. 27 900 600 86400 3600
algeta.no. 600 IN MX 20 cluster4a.eu.messagelabs.com.
algeta.no. 3600 IN MX 10 cluster4.eu.messagelabs.com.
DEL Notes:
labbetuss.net-works.no. 1440 IN A 77.40.170.151
odin.intra.itera.no. 1200 IN A 193.19.64.66
cluster4a.eu.messagelabs.com. 666 IN A 216.82.251.230
cluster4a.eu.messagelabs.com. 666 IN A 85.158.139.103
Mottatt 283 bytes fra adresse 193.19.64.66#53 i tiden på 104 ms
mottatt fra andre DNS-server
Forespørsel til serveren "algeta.no"
Du brukte følgende DNS-server:
DNS Name: labbetuss.net-works.no
DNS server adresse: 77.40.170.151#53
DNS server aliaser:
HEADER opcode: forespørsel, status: NOERROR, id: 41193
flagg: qr aa rd forespørsel: 1, Svar: 6, AUTHORITY: 0, ekstra: 1
forespørsel DEL:
algeta.no. IN ANY
Svar DEL:
algeta.no. 3600 IN SOA odin.intra.itera.no. helge.itera.no. 27 900 600 86400 3600
algeta.no. 3600 IN NS labbetuss.net-works.no.
algeta.no. 3600 IN NS odin.intra.itera.no.
algeta.no. 3600 IN A 85.221.23.130
algeta.no. 3600 IN MX 20 cluster4a.eu.messagelabs.com.
algeta.no. 3600 IN MX 10 cluster4.eu.messagelabs.com.
DEL Notes:
labbetuss.net-works.no. 1440 IN A 77.40.170.151
Mottatt 235 bytes fra adresse 77.40.170.151#53 i tiden på 103 ms
underdomener (de første 50)
Skrivefeil (feilstaver)
zlgeta.no slgeta.no wlgeta.no qlgeta.no akgeta.no apgeta.no aogeta.no alfeta.no alveta.no albeta.no alheta.no alyeta.no alteta.no algwta.no algsta.no algdta.no | algrta.no alg4ta.no alg3ta.no algera.no algefa.no algega.no algeya.no alge6a.no alge5a.no algetz.no algets.no algetw.no algetq.no lgeta.no ageta.no aleta.no | algta.no algea.no alget.no lageta.no agleta.no alegta.no algtea.no algeat.no aalgeta.no allgeta.no alggeta.no algeeta.no algetta.no algetaa.no |
Sted
IP: 85.221.23.130
kontinent: EU, land: Norway (NOR), by:
Website verdi
rang i trafikken statistikken:
Det er ikke nok data til å beregne nettstedet verdi.
Grunnleggende informasjon
nettsted bygger ved hjelp av CSS
code vekt: 18.72 KB
tekst per all kode ratio: 19 %
tittel: Algeta.com
beskrivelse:
søkeord:
koding: ISO-8859-1
språk: no
Website kodeanalyse
et ord setninger gjentas minst tre ganger
setning | Antall |
---|---|
2011 | 7 |
to | 6 |
Algeta | 5 |
and | 5 |
September | 5 |
is | 4 |
Alpharadin | 4 |
with | 4 |
at | 3 |
III | 3 |
for | 3 |
of | 3 |
Corporate | 3 |
to ord setninger gjentas minst tre ganger
setning | Antall |
---|---|
September 2011 | 5 |
2011 Algeta | 3 |
tre ord setninger gjentas minst tre ganger
setning | Antall |
---|---|
September 2011 Algeta | 3 |
B tags
U tags
I tags
bilder
file name | alternative teksten |
---|---|
logo_new3.jpg | |
sep.jpg | |
sep2.png | |
latest-news-new.jpg | |
share-price.jpg | |
orderdepths.jpg | |
h_inv.png |
overskrifter
H1
Algeta is a focused oncology company developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.
H2
H3
H4
H5
H6
interne lenker
adresse | anker tekst |
---|---|
default.asp?m=34581 | |
default.asp | Home |
dynside.asp?m=34567 | About us |
/ | About us |
/ | Products |
/ | Clinical trials |
/ | R & D |
/ | News & Media |
/ | Investors |
/ | Partners |
/ | Contact |
dynside.asp?m=34568 | Products |
/ | About us |
/ | Products |
/ | Clinical trials |
/ | R & D |
/ | News & Media |
/ | Investors |
/ | Partners |
/ | Contact |
dynside.asp?m=34573 | Clinical trials |
/ | About us |
/ | Products |
/ | Clinical trials |
/ | R & D |
/ | News & Media |
/ | Investors |
/ | Partners |
/ | Contact |
dynside.asp?m=34570 | R & D |
/ | About us |
/ | Products |
/ | Clinical trials |
/ | R & D |
/ | News & Media |
/ | Investors |
/ | Partners |
/ | Contact |
dynside.asp?m=34572 | News & Media |
/ | About us |
/ | Products |
/ | Clinical trials |
/ | R & D |
/ | News & Media |
/ | Investors |
/ | Partners |
/ | Contact |
dynside.asp?m=34571 | Investors |
/ | About us |
/ | Products |
/ | Clinical trials |
/ | R & D |
/ | News & Media |
/ | Investors |
/ | Partners |
/ | Contact |
dynside.asp?m=34579 | Partners |
/ | About us |
/ | Products |
/ | Clinical trials |
/ | R & D |
/ | News & Media |
/ | Investors |
/ | Partners |
/ | Contact |
kontakt.asp?m=34639 | Contact |
/ | About us |
/ | Products |
/ | Clinical trials |
/ | R & D |
/ | News & Media |
/ | Investors |
/ | Partners |
/ | Contact |
dynside.asp?m=34567 | About us |
dynside.asp?m=34567&s=34574 | About Algeta |
dynside.asp?m=34567&s=34653 | Corporate Strategy |
dynside.asp?m=34567&s=37440 | Management |
dynside.asp?m=34567&s=37441 | Board of Directors |
dynside.asp?m=34567&s=34657 | Code of Ethics |
dynside.asp?m=34568 | Products |
dynside.asp?m=34568&s=34658 | Pipeline |
dynside.asp?m=34568&s=34659 | Alpharadin |
dynside.asp?m=34568&s=34660 | TTC |
dynside.asp?m=34573 | Clinical trials |
dynside.asp?m=34573&s=34661 | ALSYMPCA |
dynside.asp?m=34573&s=37900 | BC1-09 Breast |
dynside.asp?m=34573&s=37901 | BC1-10 Combo |
dynside.asp?m=34570 | R & D |
dynside.asp?m=34570&s=34662 | Technology Overview |
dynside.asp?m=34570&s=37406 | Alpha-Pharmaceuticals |
xml_press.asp?m=34572 | News & Media |
xml_press.asp?m=34572&s=34686 | Press releases |
dynside.asp?m=34572&s=37448 | Events |
dynside.asp?m=34572&s=37444 | Publications PDF |
dynside.asp?m=34572&s=37446 | Pictures & logo |
dynside.asp?m=34572&s=37445 | Media contact |
subscription.asp?m=34572&s=34651 | Subscription |
dynside.asp?m=34571 | Investors |
dynside.asp?m=34571&s=34644 | Share Price Information |
reports_and_presentations2.asp?m=34571&s=34645 | Reports & Presentations |
webcast.asp?catID=webcast | Webcast |
dynside.asp?m=34571&s=34648 | Main Shareholders |
dynside.asp?m=34571&s=37438 | Oslo Stock Exchange |
dynside.asp?m=34571&s=37442 | OSE Announcements |
dynside.asp?m=34571&s=34647 | Analyst Coverage |
dynside.asp?m=34571&s=34649 | Financial Calendar |
dynside.asp?m=34571&s=54333 | AGM 2011 |
dynside.asp?m=34571&s=34650 | Corporate Governance |
dynside.asp?m=34571&s=34655 | Board of Directors |
dynside.asp?m=34571&s=34654 | Management |
subscription.asp?m=34571&s=34651 | Subscription |
dynside.asp?m=34571&s=34652 | IR contacts |
dynside.asp?m=34579 | Partners |
dynside.asp?m=34579&s=37439 | Overview |
kontakt.asp?m=34639 | Contact |
kontakt.asp?m=34639&s=34641 | Contact details |
dynside.asp?m=34639&s=34642 | Directions |
dynside.asp?m=34639&s=34640 | Careers |
/ | About us |
/ | Products |
/ | Clinical trials |
/ | R & D |
/ | News & Media |
/ | Investors |
/ | Partners |
/ | Contact |
dynside.asp?m=34568&s=34659 | Learn more > |
xml_press.asp?m=34572&s=34686 | |
dynside.asp?m=34571&s=34644 | |
dynside.asp?m=34571&s=34644 | |
dynside.asp?m=34571 | Investors |
dynside.asp?m=34568&s=34659 | Products |
dynside.asp?m=34639&s=34642 | How to find us |
dynside.asp?m=37423&s=39359 | Disclaimer |
# | Privacy statement |
eksterne linker
adresse | anker tekst |
---|---|
xml_press_underside.asp?xml=http://cws.huginonline.com/A/134655/PR/201109/1549495.xml&m=34572&s=34686&ss=&d=2011-09-26 | Algeta to Host Investor Meeting, Webcast and Conference Call to Discuss Positive Phase III Trial Results for Alpharadin |
xml_press_underside.asp?xml=http://cws.huginonline.com/A/134655/PR/201109/1549445.xml&m=34572&s=34686&ss=&d=2011-09-24 | Alpharadin Significantly Improves Overall Survival for Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases |
xml_press_underside.asp?xml=http://cws.huginonline.com/A/134655/PR/201109/1546257.xml&m=34572&s=34686&ss=&d=2011-09-14 | Algeta to Present at Forthcoming Life Sciences Investor Conferences |
xml_press_underside.asp?xml=http://cws.huginonline.com/A/134655/PR/201109/1545870.xml&m=34572&s=34686&ss=&d=2011-09-13 | Alpharadin Phase III Trial Data to be presented at Best and Late-Breaking Session at the 2011 European Multidisciplinary Cancer Congress |
xml_press_underside.asp?xml=http://cws.huginonline.com/A/134655/PR/201109/1544704.xml&m=34572&s=34686&ss=&d=2011-09-08 | Algeta appoints Mike Booth as Senior Vice President, Communications and Corporate Affairs |
http://media01.smartcom.no/Microsite/start.aspx?eventid=6390 | Webcast |
http://kundeweb.aggressive.no/users/algeta2.no/Annual Report 2010/index.html | Annual Report 2010 |
http://media01.smartcom.no/Microsite/start.aspx?eventid=6390 | Webcast |